Vaccine Immunization route No. of doses Developer Status References
Shigellosis          
Attenuated S. sonnei strain WRSS1 Oral 2 Walter Reed Army Institute of Research Phase II [70]
Attenuated S. flexneri2a strain CVD 1208S Oral 2 Center for Vaccine Development, University of Maryland Phase I [74]
Attenuated S. flexneri2a strain SC602 Oral 1-2 Pasteur Institute Phase II [71]
Attenuated S. dysenteriae 1 strain SC599 Oral 2 Pasteur Institute Phase II [73]
Shigellaglycoconjugates (O polysaccharide covalently linked to carrier protein) Intra-muscular 2 National Institute ofHealth and Human Development Phase III [65]
Shigella invasion complex (Invaplex) Nasal 3 Walter Reed Army Institute of Research Phase I [68]
Proteosomes (OMP of Group B meningitides) to which S. sonnei or S. flexneri2a LPS is adsorbed Nasal 2 ID Biomedical* Phase I [69]
ETEC diarrhea          
B subunit-inactivated whole fimbriated ETEC combination Oral 2 University of Goteborg and SBL Phase III [82]
Attenuated fimbriated non-toxigenic E. coli (derived from ETEC) Oral 2 Cambridge Biostability Ltd. Phase I [88]
Attenuated Shigella strains expressing ETEC fimbrial colonization factors and B subunit of LTh** Oral 2 Center for Vaccine Development, University of Maryland Phase I [86]
Table 2: New generation unlicensed vaccines against Shigella and ETEC (adapted from ref. 3). *Now GSK Biologicals. **LTh, LT from a human ETEC strain.